Search details
1.
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
J Transl Med
; 19(1): 17, 2021 01 06.
Article
in English
| MEDLINE | ID: mdl-33407577
2.
Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
J Transl Med
; 19(1): 132, 2021 03 31.
Article
in English
| MEDLINE | ID: mdl-33789686
3.
BRAF Gene and Melanoma: Back to the Future.
Int J Mol Sci
; 22(7)2021 Mar 27.
Article
in English
| MEDLINE | ID: mdl-33801689
4.
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Cancer Immunol Immunother
; 63(7): 675-83, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24695951
5.
Do BRAF inhibitors select for populations with different disease progression kinetics?
J Transl Med
; 11: 61, 2013 Mar 08.
Article
in English
| MEDLINE | ID: mdl-23497384
6.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol
; 41(2): 212-221, 2023 01 10.
Article
in English
| MEDLINE | ID: mdl-36049147
7.
Epigenetic Regulation in Melanoma: Facts and Hopes.
Cells
; 10(8)2021 08 11.
Article
in English
| MEDLINE | ID: mdl-34440824
8.
Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes' iTNF-α Expression.
Biology (Basel)
; 10(8)2021 Aug 01.
Article
in English
| MEDLINE | ID: mdl-34439967
9.
Nivolumab for the treatment of small cell lung cancer.
Expert Rev Respir Med
; 14(1): 5-13, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31622114
10.
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
J Immunother Cancer
; 8(2)2020 08.
Article
in English
| MEDLINE | ID: mdl-32784217
11.
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
J Immunother Cancer
; 8(2)2020 10.
Article
in English
| MEDLINE | ID: mdl-33060148
12.
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.
PLoS One
; 14(1): e0210330, 2019.
Article
in English
| MEDLINE | ID: mdl-30620767
13.
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib.
Oncotarget
; 9(15): 12408-12417, 2018 Feb 23.
Article
in English
| MEDLINE | ID: mdl-29552321
14.
Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.
Oncoimmunology
; 6(3): e1283462, 2017.
Article
in English
| MEDLINE | ID: mdl-28405510
15.
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.
Oncoimmunology
; 4(6): e1008842, 2015 Jun.
Article
in English
| MEDLINE | ID: mdl-26155423
16.
Serious haematological toxicity during and after ipilimumab treatment: a case series.
J Med Case Rep
; 8: 240, 2014 Jul 01.
Article
in English
| MEDLINE | ID: mdl-24986059
17.
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
Oncoimmunology
; 3: e28780, 2014.
Article
in English
| MEDLINE | ID: mdl-25083318
Results
1 -
17
de 17
1
Next >
>>